Project Grant R01CA308029
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $804K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Institute of General Medical Sciences awarded Sanford Burnham Prebys Medical Discovery Institute $2,903,176 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms of nuclear pore complex formation. The project, titled "Molecular Basis of Nuclear Pore Formation," will define regulatory principles governing nuclear pore biogenesis in mammalian cells. The research addresses how alterations in...
- The National Cancer Institute awarded $633,126 to Beckman Research Institute of the City of Hope on July 20, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of PUS1-mediated mRNA pseudouridine modification in acute myeloid leukemia pathogenesis. The project will define the oncogenic role of PUS1 in AML pathogenesis and elucidate how PUS1-mediated mRNA pseudouridine modification promotes leukemogenesis through post-transcriptional regulation of gene...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded the University of California, San Diego $663,998 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct mechanistic research on targeting the Type I interferon pathway to improve cancer therapy efficacy. The research investigates how ubiquitin specific protease 18 (USP18) negatively regulates interferon signaling in cancer cells and tests whether blocking USP18-mediated suppression of the interferon response can enhance the...
- The National Institutes of Health National Cancer Institute awarded The Research Foundation For The State University Of New York $724,196 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) for a Project Grant (R01CA308325) investigating HLA-independent CD8+ T cell immunotherapy against acute myeloid leukemia. The research develops a novel therapeutic strategy to overcome HLA Class I downregulation on leukemic cells, which enables tumors to evade conventional CD8+ T...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Cancer Institute (a component of the Department of Health and Human Services National Institutes of Health) awarded Northwestern University $1,431,654 on September 23, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate how leukemia stem cell persistence during tyrosine kinase inhibitor treatment in chronic myeloid leukemia is influenced by interaction with CD8+ T cells. The research will employ single-cell RNA sequencing and murine transplant models to...